{Reference Type}: Journal Article
{Title}: Recent advances in multidisciplinary therapy for adenocarcinoma of the esophagus and esophagogastric junction.
{Author}: Zheng YH;Zhao EH;
{Journal}: World J Gastroenterol
{Volume}: 28
{Issue}: 31
{Year}: Aug 2022 21
{Factor}: 5.374
{DOI}: 10.3748/wjg.v28.i31.4299
{Abstract}: Esophageal adenocarcinoma (EAC) and adenocarcinoma of the esophagogastric junction (EGJA) have long been associated with poor prognosis. With changes in the spectrum of the disease caused by economic development and demographic changes, the incidence of EAC and EGJA continues to increase, making them worthy of more attention from clinicians. For a long time, surgery has been the mainstay treatment for EAC and EGJA. With advanced techniques, endoscopic therapy, radiotherapy, chemotherapy, and other treatment methods have been developed, providing additional treatment options for patients with EAC and EGJA. In recent decades, the emergence of multidisciplinary therapy (MDT) has enabled the comprehensive treatment of tumors and made the treatment more flexible and diversified, which is conducive to achieving standardized and individualized treatment of EAC and EGJA to obtain a better prognosis. This review discusses recent advances in EAC and EGJA treatment in the surgical-centered MDT mode in recent years.